A Study of Clearance of Infection in HIV-Associated Cryptococcal Meningitis after Amphotericin-Based Induction and Fluconazole-Based Consolidation Therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
A Study of Clearance of Infection in HIV-Associated Cryptococcal Meningitis after Amphotericin-Based Induction and Fluconazole-Based Consolidation Therapy ; year:2021
International journal of recent surgical and medical science ; (2021)
- Contributor
-
Devi, Sorokhaibam Bhagyabati
Navi, Raghavendra Ashok
Suraj, Thangjam
Reema, Ningthoukhongjam
Singh, Thangjam Gautam
Kuotsu, Medo M.
Konyak, Nyamnyei
- DOI
-
10.1055/s-0041-1723920
- URN
-
urn:nbn:de:101:1-2021031909231893105691
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Devi, Sorokhaibam Bhagyabati
- Navi, Raghavendra Ashok
- Suraj, Thangjam
- Reema, Ningthoukhongjam
- Singh, Thangjam Gautam
- Kuotsu, Medo M.
- Konyak, Nyamnyei
Other Objects (12)
Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China
Thalidomide for Recurrence of Symptoms following HIV-Associated Cryptococcal Meningitis
High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis
HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings
HIV-associated Cryptococcal Meningitis: a Review of Novel Short-Course and Oral Therapies
Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study
Evaluation of the initial 12 months of a routine cryptococcal antigen screening program in reduction of HIV-associated cryptococcal meningitis in Uganda
K21 Compound, a Potent Antifungal Agent: Implications for the Treatment of Fluconazole-Resistant HIV-Associated Candida Species
Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre™ YeastOne™ YO9 platform
The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
High-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis
Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China
Thalidomide for Recurrence of Symptoms following HIV-Associated Cryptococcal Meningitis
High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis
HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings
HIV-associated Cryptococcal Meningitis: a Review of Novel Short-Course and Oral Therapies
Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study
Evaluation of the initial 12 months of a routine cryptococcal antigen screening program in reduction of HIV-associated cryptococcal meningitis in Uganda
K21 Compound, a Potent Antifungal Agent: Implications for the Treatment of Fluconazole-Resistant HIV-Associated Candida Species
Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre™ YeastOne™ YO9 platform
The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
High-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis
Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China
Thalidomide for Recurrence of Symptoms following HIV-Associated Cryptococcal Meningitis
High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis
HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings
HIV-associated Cryptococcal Meningitis: a Review of Novel Short-Course and Oral Therapies
Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study
Evaluation of the initial 12 months of a routine cryptococcal antigen screening program in reduction of HIV-associated cryptococcal meningitis in Uganda
K21 Compound, a Potent Antifungal Agent: Implications for the Treatment of Fluconazole-Resistant HIV-Associated Candida Species
Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre™ YeastOne™ YO9 platform
The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole